Artelo Biosciences
ARTL
0 hedge funds and large institutions have $0 invested in Artelo Biosciences in 2020 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0.43% less ownership
Funds ownership: 0.44% → 0% (-0.43%)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $18K → $0 (-$18K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$17K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
ARTL Hedge Fund Activity: Q3 2020 in Review
0 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2020, worth a combined $0 — down 100% from $18K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ARTL and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Goldman Sachs, exiting entirely with an estimated $17K sold.
- 0 institutional investors held Artelo Biosciences (ARTL) as of Q3 2020, down from 1 in Q2 2020.
- Funds reported $0 of Artelo Biosciences stock for Q3 2020, down 100% quarter-over-quarter.
- 0 funds opened new Artelo Biosciences positions in Q3 2020 and 1 closed out, a net change of -1 holder.
- The largest Artelo Biosciences seller in Q3 2020 was Goldman Sachs, an estimated $17K sold.
Based on aggregated 13F filings for Q3 2020.